Screener
ImmunityBio, Inc. IBRX Reportable Segment — R&D
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:37 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326110-26-000059
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Equipment, depreciation, and facility costs | 13,588 | 13,192 |
| Other research and development costs | 8,469 | 6,466 |
| Total internal research and development expense | 47,907 | 42,723 |
| Total research and development expense (including amounts with related parties) | 67,989 | 48,234 |
| Selling, general and administrative (including amounts with related parties) | 45,770 | 32,654 |
| Total operating expenses | 113,759 | 80,888 |
| Loss from operations | (69,791) | (64,429) |
| Other income (expense), net |
ITEM 1. FINANCIAL STATEMENTS.
FAQ
- What is ImmunityBio, Inc.'s reportable segment — R&D?
- ImmunityBio, Inc. (IBRX) reported reportable segment — R&D of $67.99M in Q1 2026.
- How has ImmunityBio, Inc.'s reportable segment — R&D changed year-over-year?
- ImmunityBio, Inc.'s reportable segment — R&D increased by 41.0% year-over-year, from $48.23M to $67.99M.
- What is the long-term trend for ImmunityBio, Inc.'s reportable segment — R&D?
- Over 3 years (2022 to 2025), ImmunityBio, Inc.'s reportable segment — R&D has grown at a 5.5% compound annual growth rate (CAGR), from $186.34M to $218.56M.
- What does reportable segment — R&D mean?
- The aggregate of all expenses related to the discovery, development, and clinical testing of new products within the segment. This is the primary investment driver for future growth in biotechnology companies.
Ask your AI about ImmunityBio, Inc.'s reportable segment — r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude